Get started
Adlai Nortye Ltd.Adlai Nortye Ltd.Adlai Nortye Ltd.

Adlai Nortye Ltd.

No trades
See on Supercharts
Overview
Financials News Discussions Technicals Seasonals

ANL chart


Full chart

ANL upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪70.48 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
—
Net income (FY)
‪−104.78 M‬ USD
Revenue (FY)
‪5.00 M‬ USD
Shares float
—
Beta (1Y)
1.20

About Adlai Nortye Ltd.


Sector
Commercial Services
Industry
Miscellaneous Commercial Services
CEO
Yang Lu
Website
adlainortye.com
Headquarters
Hangzhou
Founded
2018
FIGI
BBG01HP11SV4
Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ANL news



Technicals


Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as ANL.